Annexon
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 71
- Market Cap
- $639.2M
- Website
- http://www.annexonbio.com
- Introduction
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.
Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less ...
Annexon, Inc. announced new ANX007 analyses from the Phase 2 ARCHER trial in geographic atrophy (GA) at the AAO 2024 annual meeting and Eyecelerator conference. ANX007, a non-pegylated Fab designed to block C1q locally in the eye, demonstrated significant vision protection and photoreceptor preservation in the fovea region. Phase 3 data from the ongoing ARCHER II pivotal program is expected in the second half of 2026.
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy (GA)
Annexon presents ANX007 Phase 2 ARCHER trial data in geographic atrophy (GA) at Retina Society and Euretina Congress, demonstrating vision protection and photoreceptor preservation, with Phase 3 ARCHER II trial initiated.
© Copyright 2025. All Rights Reserved by MedPath